Enlivex Therapeutics Ltd.
ENLVNext catalyst
Allocetra
Osteoarthritis, Knee
Get an email about ENLV's next catalysts
Track Enlivex Therapeutics (ENLV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 4 past
Allocetra Phase 2 Est. Readout
Estimated primary completion for Allocetra trial (NCT07580716) in Primary Knee Osteoarthritis. Topline data typically follows completion by weeks to months.
SourceHow ENLV's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Allocetra | Phase 2 | Osteoarthritis, Knee | - | - |
Allocetra-OTS | Phase 2 | Sepsis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Enlivex Therapeutics Ltd.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Enlivex Therapeutics Ltd.'s (ENLV) pipeline across Phase 2. Its lead program is Allocetra (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enlivex Therapeutics Ltd.'s next FDA catalyst?β
Enlivex Therapeutics Ltd.'s (ENLV) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENLV biotech catalysts?β
Add ENLV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enlivex Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
